Topic:

Emerging Markets

Latest Headlines

Latest Headlines

Takeda strikes $400M IT services deal with Wipro

Wipro has won a $400 million contract to manage Takeda's infrastructure. Takeda inked the deal to consolidate its operations, with Wipro becoming its primary provider of IT infrastructure management services.

Emerging market playbook: Egypt's Amoun Pharma puts itself on the block

Any pharma company looking for growth in Egypt has a new target to consider: Amoun Pharmaceutical, one of that country's largest drugmakers. Amoun has hired Jeffries Group to explore a potential sale, Bloomberg reports.

Abbott expands manufacturing in Latin America with CFR deal

Abbott gets a portfolio of 1,000 new drugs and expects to see its sales in the Latin American market double with its $3 billion buyout out of Chile's CFR Pharmaceutical.

Biosensors International unveils innovative bare-metal stent system

Biosensors International unveiled its innovative bare-metal cobalt chromium system months after rumors of a takeover.

WuXi wraps up construction on a new biologics shop

China's WuXi PharmaTech has completed work on a biologics safety testing facility in Suzhou, adding 38,000 square feet of lab space to its sprawling presence in the area.

Emboldened by their GSK probe, Chinese officials step up pharma snooping

Pharma industry probes are far from over, China-based professionals say. And with the country trying desperately to drive down healthcare costs for its population of close to 1.4 billion, Big Pharma had best be careful. Local officials are making it clear that Big Brother is watching.

First, bribery. Now, China floats tax-evasion accusations against GlaxoSmithKline

More accusations against GlaxoSmithKline are flying in China, but this time they're not about bribery. They're about taxes. A government-run legal newspaper alleges that the British drug giant evaded millions in taxes, compounding the company's growing problems in the country.

WuXi scores more double-digit growth amid its global expansion

Chinese CRO WuXi PharmaTech notched another strong sales quarter, boosting its revenue by 11.3% thanks to escalating demand for its manufacturing services.

Xinhua: Multinationals, beware--or end up like Glaxo

"Ethics matter" in China--and it's time for multinationals to take note, according to the country's official news agency. With a reputation-tarnishing scandal, dented China sales and a former top exec facing up to a lifetime in prison, GlaxoSmithKline's tale should serve as a prime example of what can happen if they don't.

3-D printed prosthesis enables Haitian orphan to use hand

A Haitian orphan born without fingers on both hands became the first beneficiary of a 3-D printed prosthesis in that country last month. Britain's John Marshall and South Africa's Richard van As developed the prosthesis. The printing cost was only $300.